A case report: interstitial pneumonia following treatment of gastric cancer with sintilimab in combination with S-1
This case provides a clinical reference, indicating that prior touse of sintilimab in combination with S-1 antitumor regimen, a comprehensive baseline assessment should be conducted, including blood routine examination, enzyme tests, and pulmonary imaging examination, with close monitoring of the patient's pulmonary condition. If drug-induced lung injury is suspected, the medication should be discontinued immediately, and appropriate treatment should be initiated promptly.
Authors
- Wanhui Dong (ORCID: https://orcid.org/0000-0002-6470-4643)
- Sheng Xu (ORCID: https://orcid.org/0000-0002-6507-9122)
- Qingming Sun
- Pei Zhu
Institutions
- Anhui University of Traditional Chinese Medicine (CN)
- Lu'an First People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-05
- DOI
- https://doi.org/10.3389/fphar.2025.1508558
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00